A study of HIV provider attitudes toward HLA-B*5701 testing in the United States

AIDS Patient Care and STDs

Volumn 23, Issue 11, 2009, Pages 957-963

  Watson, Maria E ^a   Patel, Lisa G ^a   Ha, Belinda ^a   Wannamaker, Paul ^a   Cuffe, Robert ^b   Shaefer, Mark ^a  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; HLA B ANTIGEN;

ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; DIAGNOSTIC KIT; EDUCATION PROGRAM; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; REIMBURSEMENT; SCREENING TEST; UNITED STATES;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE OF HEALTH PERSONNEL; CASE-CONTROL STUDIES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HISTOCOMPATIBILITY TESTING; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 72849137302     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0245     Document Type: Article

References (22)

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-1614.
2. Hernandez JE, Cutrell A, Edwards M, et al. Clinical risk factors for hypersensitivity reactions to abacavir: Retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials [Abstract 339]. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: September 14-17, 2003.
3. Ziagen [package insert]. www.fda.gov=cder=foi=label=2008= 020977s019,020978s022lbl.pdf (Last accessed April 2009).
4. Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir [letter]. Ann Pharmacother 2004;38: 2171-2172.
5. Peyrieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of a family [letter]. Ann Pharmacother 2001;35:1291-1292.
6. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
7. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-1122.
8. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-211.
9. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-4185.
10. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579.
11. Saag M, Balu R, Brachman P, et al. High sensitivity of HLAB* 5701 in immunologically-confirmed cases of abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-1118.
12. Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008;22:1673-1675.
13. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
14. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity [Abstract 14]. Antivir Ther 2006;11(suppl):L11.
15. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007;45:1-3.
16. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: A single centre experience. AIDS 2007;21:2533-2534.
17. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; pp. 1-128. Available at www.aidsinfo.nih.gov=ContentFiles=AdultandAdolescentGL. pdf (Last accessed September 11, 2008).
18. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society USA Panel. JAMA 2008;300:555-570.
19. Phillips EJ. The pharmacogenetics of antiretroviral therapy. Curr Opin HIV AIDS 2006;1:249-256.
20. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-2033.
21. Farkouh R, Earnshaw SR, Kauf TL, Watson ME, Maroudas P. Cost-effectiveness of HLA-B*5701 testing prior to initiation of abacavir sulfate [Poster P9329]. 18th International AIDS Conference. 2008. Mexico City, Mexico: August 3-8, 2008.
22. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001;62:1009-1030.